New pill shows promise for rare tumor in japanese patients
NCT ID NCT07170644
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This phase 2 study tests the drug nirogacestat in 20 Japanese adults with desmoid tumors that are growing. The goal is to see if the drug can shrink tumors or stop them from getting worse. Participants take nirogacestat as an oral tablet, and researchers will monitor tumor response and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nirogacestat (oral tablet)
What this could lead to
If successful, nirogacestat could offer a new treatment option for Japanese patients with desmoid tumors, potentially shrinking tumors and delaying progression without surgery.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply to all patients. The drug may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DESMOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nagoya University Hospital
Nagoya, Aichi-ken, 466-8560, Japan
-
National Cancer Center Hospital
Chuo Ku, Tokyo, 104-0045, Japan
-
Osaka International Cancer Institute
Osaka, 541-8567, Japan